| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | -0.1 | 0.04 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.094 | 0.04 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | 0.081 | 0.08 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.074 | 0.1 |
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | 0.083 | 0.1 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.07 | 0.1 |
| mRNA | TAE684 | CCLE | pan-cancer | AAC | -0.064 | 0.2 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.057 | 0.2 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.056 | 0.2 |